dc.contributor.author | Prieto-Torres, Lucia | |
dc.contributor.author | Rodriguez-Pinilla, Socorro M. | |
dc.contributor.author | Onaindia, Arantza | |
dc.contributor.author | Ara, Mariano | |
dc.contributor.author | Requena Caballero, Luis | |
dc.contributor.author | Piris, Miguel | |
dc.contributor.other | UAM. Departamento de Anatomía Patológica | es_ES |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) | es_ES |
dc.date.accessioned | 2019-10-25T13:26:40Z | |
dc.date.available | 2019-10-25T13:26:40Z | |
dc.date.issued | 2019-01-31 | |
dc.identifier.citation | Haematologica 104.2 (2019): 226-235 | es_ES |
dc.identifier.issn | 0390-6078 (print) | es_ES |
dc.identifier.issn | 1592-8721 (online) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/688989 | |
dc.description.abstract | Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets. | en_US |
dc.description.sponsorship | This work was supported by grants from the Instituto de Salud
Carlos III (ISCIII) of the Spanish Ministry of Economy and
Competence (MINECO, RTICC ISCIII and CIBERONC)
(SAF2013-47416-R, RD06/0020/0107-RD012/0036/0060
and Plan Nacional I+D+I: PI17/2172, PI16/01294 and
PIE15/0081), AECC and the Madrid Autonomous Community. | en_US |
dc.format.extent | 10 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Ferrata Storti Foundation | es_ES |
dc.relation.ispartof | Haematologica | es_ES |
dc.rights | © 2019 Ferrata Storti Foundation | es_ES |
dc.subject.other | CD30-positive | en_US |
dc.subject.other | T-cell | en_US |
dc.subject.other | Lymphoproliferative | en_US |
dc.subject.other | Cutaneous | en_US |
dc.subject.other | Molecular alterations | en_US |
dc.title | CD30-positive primary cutaneous lymphoproliferative disorders: Molecular alterations and targeted therapies | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | https://doi.org/10.3324/haematol.2018.197152 | es_ES |
dc.identifier.doi | 10.3324/haematol.2018.197152 | es_ES |
dc.identifier.publicationfirstpage | 226 | es_ES |
dc.identifier.publicationissue | 2 | es_ES |
dc.identifier.publicationlastpage | 235 | es_ES |
dc.identifier.publicationvolume | 104 | es_ES |
dc.relation.projectID | Gobierno de España. SAF2013-47416-R | es_ES |
dc.relation.projectID | Gobierno de España. RD06/0020/0107 | es_ES |
dc.relation.projectID | Gobierno de España. RD012/0036/0060 | es_ES |
dc.relation.projectID | Gobierno de España. PI17/2172 | es_ES |
dc.relation.projectID | Gobierno de España. PI16/01294 | es_ES |
dc.relation.projectID | Gobierno de España. PIE15/0081 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento – NoComercial | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Rodríguez Pinilla, Socorro María (262752) | |
dc.authorUAM | Requena Caballero, Luis (258697) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) | |